Flowchart of participants included in the analytical sample. The Canadian Co-Infection Cohort (CCC) had recruited 2018 HIV-HCV coinfected participants (HCV RNA positive/HCV seropositive) until July 2020. In our analysis, we included 503 participants who were treated with IFN-free second-generation direct acting antiviral (DAA) regimens after 25 November 2013, when the first second-generation DAA, Simeprevir, was approved for use by Health Canada. Of the participants who were treated, we excluded those who did not achieve sustained virologic response (SVR) (n = 32) and did not have a treatment response date (n = 1). Thus, in the final analytical sample we included a total of 470 participants who had achieved SVR. Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus; IFN, interferon.